Pharmacological Treatment Pattern and Comorbidities in Parkinson’s Disease Outpatients at Dr. Hasan Sadikin General Hospital Bandung in 2013–2018

Elke Feliciana, Paulus Anam Ong, Sobaryati Sobaryati


Background: Parkinson’s disease (PD) is one of many neurodegenerative diseases with symptomatic management, and with the correct pattern of pharmacological treatment PD may have an improved quality of life for a minimum of three years. This study aimed to illustrate treatment patterns and comorbidities in PD patients at Dr. Hasan Sadikin General Hospital, Bandung.

Methods: This study was a cross-sectional descriptive study by using total medical records of the period of 2013 to 2018. PD patients receiving pharmacological treatments such as levodopa, anticholinergics, dopamine agonists, or combined therapy were included. Patients with incomplete data and with the previous history of other neurological diseases before PD were excluded from this study.

Results: In total, there were 57 patients with PD, of whom most of them were males (79%). Age-wise, PD was most common in 60 to 69-year-olds (32%). The most commonly used treatment pattern was the administration of levodopa (33%). Patients aged younger than 30 years were administered anticholinergics, whereas the older patients (>60 years old) mostly were given levodopa. Comorbidities after PD diagnosis were mostly stroke, dementia, and epilepsy.

Conclusions: Males are most affected by PD, and the most commonly used treatment pattern is levodopa monotherapy. PD is most commonly found in patients aged 60 to 69 years. Patients aged below 30 years are administered anticholinergics. The most common comorbidities found are a stroke, followed by dementia and epilepsy. By recognizing the patterns and comorbidities of this disease, the study may provide some insights into choosing the most effective pharmacological therapy for PD.



omorbidities, Parkinson’s disease, pharmacological treatment

Full Text:



Standaert D, Marie , Thomas C.,et al. Parkinson’s Disease Handbook. New York: American Parkinson Disease Association;2014

Jankovic J. Parkinson ’ s disease : clinical features and diagnosis. 2008:368–76.

Colamartino M, Padua L, Cornetta T, Testa A, Cozzi R. Recent advances in pharmacological therapy of Parkinson ’ s disease : Levodopa and carbidopa protective effects against DNA oxidative damage. 2012;4:1191–9.

Connolly BS, Lang AE. Pharmacological Treatment of Parkinson Disease. Jama . 2014;311(16):1670

Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): A large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196–205.

Brooks DJ. Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: Implications from a clinical and patient perspective. Neuropsychiatric Disease Treatment. 2008;4(1 A):39–47

Wang X, Zeng F, Jin W, Zhu C, Wang Q, Bu X, et al. Comorbidity burden of patients with Parkinson ’ s disease and Parkinsonism between 2003 and 2012 : A multicentre , nationwide , retrospective study in China. Sci Rep . 2017;(March):1–6.

Picillo M, Nicoletti A, Fetoni V, Garavaglia B, Barone P, Teresa M. The relevance of gender in Parkinson ’ s disease : a review. J Neurol. 2016.

Hospital L, Road H. Ageing , neurodegeneration and Parkinson ’ s disease. 2010;(January):156–61.

Reeve A, Simcox E, Turnbull D. Ageing and Parkinson ’ s disease : Why is advancing age the biggest risk factor ? Ageing Res Rev . 2014;14:19–30.

Chen S, Chan P, Sun S, Chen H, Zhang B, Le W, et al. The recommendations of Chinese Parkinson ’ s disease and movement disorder society consensus on therapeutic management of Parkinson ’ s disease. Translation Neurodegeneration . 2016;1–12.

Worth PF. How to treat Parkinson ’ s disease in 2013. 2013;13(1):93–6.

Matarazzo M, Perez-Soriano A & Stoessl AJ. Neural Transmission (2018) 125:1119

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The Pharmacology of L -DOPA-Induced Dyskinesia in Parkinson ’ s Disease. 2013 January:171–222.

Stocchi F, Vacca L, Radicati FG. How to optimize the treatment of early stage Parkinson ’ s disease. 2015;1–7.

Chen S, Chan P, Sun S, Chen H, Zhang B, Le W, et al. The recommendations of Chinese Parkinson ’ s disease and movement disorder society consensus on therapeutic management of Parkinson ’ s disease. Transl Neurodegener . 2016;1–12.

Hindle JV. Ageing, neurodegeneration and Parkinson's disease. Age Ageing. 2010;39(2):156–61.

Doherty GH. Homocysteine and Parkinson’s Disease: A Complex Relationship. 2013;1(1):1–9.


Article Metrics

Abstract view : 414 times
PDF - 267 times

 This Journal indexed by


Creative Commons License
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License


View My Stats